NCT05251727 2024-08-19
Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients
Veloxis Pharmaceuticals
Phase 1 Terminated
Veloxis Pharmaceuticals
University of Wisconsin, Madison
Tarix Pharmaceuticals
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins